Trial Profile
Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Dec 2015 New trial record